Lesson
Understand the Product Before the Dose
Immune globulin is purified polyclonal human IgG collected from many donors. Its biologic behavior reflects the donor antibody repertoire, manufacturing process, route, formulation, distribution, and patient clearance rather than one small-molecule target.
- Pooled IgG
- Polyclonal antibodies
- Fc and Fab functions
- Manufacturing safeguards
- Passive immunity
- Pharmacokinetics
Many plasma donors contribute broad polyclonal recognition
Screening, testing, purification, and pathogen reduction lower risk
Antigen binding and immune regulation support different clinical roles
Route, protein loss, inflammation, and individual clearance shape duration
Separate passive antibody from active immunity
Immune globulin supplies antibodies immediately but does not train the recipient's immune system in the same way as vaccination. The transferred antibodies decline as IgG is distributed and cleared.
Keep Fc and Fab biology connected
Fab regions recognize many antigens. Fc interactions influence immune cells, complement, antibody recycling, and inflammatory signaling. High immunomodulatory doses use several mechanisms rather than one universal pathway.
Respect donor and manufacturing controls
Products are made from large plasma pools with donor screening, testing, purification, and pathogen reduction steps. A residual theoretical infection risk remains, so traceability and adverse-event investigation matter.
Expect patient-specific exposure
Distribution, ongoing protein loss, infection burden, inflammation, body composition, route, dose interval, and individual clearance can change the achieved IgG concentration and clinical response.
Do not treat a class as one formulation
Concentration, stabilizer, osmolality, sodium, IgA content, pH, route, approved indications, infusion rate, storage, and preparation differ by product and can alter selection and tolerability.
Quick check
Lesson
Define the Clinical Role Before Choosing a Product
Immune globulin can replace missing antibody, modulate immune disease, or provide pathogen-specific postexposure protection. These roles differ in product, dose, route, evidence, urgency, endpoint, and regulatory status.
- Primary immunodeficiency
- Secondary immunodeficiency
- ITP
- CIDP
- Kawasaki disease
- Hyperimmune globulins
Reduce serious and recurrent infection in a defined immune deficiency
Use disease-specific evidence and an explicit response measure
Select the named pathogen-specific hyperimmune product
Continue only when benefit, need, and safety remain visible
Use replacement for clinically meaningful antibody failure
Replacement therapy is guided by immune diagnosis, infection history, antibody function, prior treatment, IgG exposure, and clinical response. A low IgG value alone does not define every indication.
Use immunomodulation by disease and evidence
FDA-approved indications vary by product and can include ITP, CIDP, Kawasaki disease, or other conditions. Neurologic, hematologic, dermatologic, and transplant uses outside labeling require indication-specific evidence and specialist oversight.
Keep hyperimmune products separate
Rabies, hepatitis B, tetanus, varicella, cytomegalovirus, vaccinia, and other pathogen-specific products have their own units, routes, timing, sites, and labels. They are not generic substitutes for IVIG or SCIG.
Name the endpoint
Replacement aims to reduce serious and recurrent infections and preserve function. Immunomodulatory therapy may target platelet recovery, neurologic strength, relapse prevention, inflammation, or organ protection.
Set a stop or renewal rule
Document how response, toxicity, alternative therapy, disease course, and ongoing need will be reassessed. Chronic continuation without an indication-specific outcome can hide ineffective or duplicative treatment.
Quick check
Lesson
Build IVIG as a Complete Infusion Order
An IVIG order is not only grams per kilogram. It must identify the exact product, indication, dosing weight method, total dose, schedule, concentration, initial and maximum rates, line instructions, monitoring, reaction plan, and traceability.
- Indication-specific dose
- Dosing weight
- Infusion rate
- Hydration
- Line compatibility
- Traceability
Verify the exact label, route, regimen, and treatment goal
State the method, exact grams, schedule, and rounding
Start low, escalate by label, and reassess at each step
Record vials, rates, reactions, intervention, and outcome
Use an indication-specific regimen
Replacement commonly uses lower recurring doses, while immunomodulatory courses may deliver a larger total dose over one or more days. Exact regimen, maximum dose, interval, and duration are disease and product specific.
Define the dosing weight policy
Actual, ideal, or adjusted body weight policies differ by indication, institution, obesity context, evidence, payer, and product. State the chosen weight and rationale rather than allowing an automatic calculation to decide silently.
Program the rate, not only the volume
Start at the product's labeled initial rate and increase in steps only when tolerated. Previous tolerance does not remove the need to consider current infection, hydration, organ function, dose, and product.
Protect the infusion system
Inspect the solution, use the labeled preparation and tubing instructions, avoid shaking, use a dedicated line when directed, and do not mix products or other medicines without verified compatibility.
Document product and lot
Record exact brand, concentration, total grams, vial sizes, lot numbers, expiration, site, rate history, reactions, interventions, and outcome. This supports continuity, recall response, and causality assessment.
Quick check
Lesson
Use SCIG as a Different Pharmacokinetic System
Subcutaneous immune globulin produces slower absorption, steadier exposure, smaller systemic peaks, and more local reactions than IVIG. Conventional and hyaluronidase-facilitated products also use different schedules and techniques.
- Conventional SCIG
- Facilitated SCIG
- Bioavailability
- Dose conversion
- Local reactions
- Home administration
Do not infer bioavailability or schedule from equal milliliters
Match volume, rate, needle, pump, and aseptic technique
Protect the dual-component sequence and ramp-up when used
Validate technique and build routine, urgent, and emergency pathways
Do not convert by intuition
Dose conversion from IVIG or between SCIG products follows the selected label and indication. Some products use a dose adjustment factor, while others use the same previous dose after a ramp-up. Confirm the current package insert.
Expect a different concentration curve
SCIG absorption is slower and exposure is steadier. A concentration drawn and interpreted as an IVIG trough may not answer the same question after route conversion.
Separate conventional from facilitated therapy
Conventional SCIG usually uses smaller, more frequent infusions. Hyaluronidase-facilitated SCIG permits larger volumes and longer intervals but requires its ordered sequence and product-specific precautions.
Teach local reaction management
Swelling, erythema, warmth, itching, discomfort, and firmness are common early and may improve with technique and experience. Severe pain, spreading infection, necrosis, or systemic symptoms require assessment.
Validate home competence
Before independent use, confirm product storage, dose preparation, pump or manual technique, asepsis, site selection, needle placement, rate, sharps disposal, logging, and emergency response.
Quick check
Lesson
Select the Product From the Patient's Constraints
The best immune globulin product is the one whose labeled indication, route, concentration, formulation, risk profile, access requirements, and prior tolerance fit the patient and treatment setting.
- Label indication
- Concentration and volume
- Stabilizer
- IgA content
- Renal risk
- Access and supply
Confirm exact approved use and age before comparing convenience
Review volume, stabilizer, sodium, osmolality, pH, and IgA
Integrate kidney, cardiac, thrombotic, allergy, and prior tolerance
Treat substitution or home transition as a new clinical plan
Begin with indication and route
Confirm that the product is licensed for the intended route and indication. A product approved for PI by two routes may not carry the same neurologic or hematologic indication by both routes.
Match concentration to volume and access
Higher concentration can reduce infusion volume but does not automatically make a product safer. Consider venous access, subcutaneous site capacity, heart failure, fluid tolerance, home logistics, and pump limits.
Read excipients and physical properties
Stabilizers, sodium, osmolality, pH, IgA content, and sugar content differ. Current products do not all contain sucrose, and class warnings should not be converted into a claim about one formulation.
Handle IgA risk precisely
IgA deficiency alone is not a universal contraindication. Product labeling may contraindicate use when anti-IgA antibodies and a history of hypersensitivity are present. Review the exact history and label.
Plan for availability without casual substitution
Supply or payer changes may require another product. Reassess indication, concentration, route, dose conversion, rate, prior reactions, training, and monitoring as a clinical transition.
Quick check
Lesson
Prevent and Manage Infusion Reactions Without Masking Danger
Many symptoms are rate related, but headache, flushing, chills, chest discomfort, dyspnea, hypotension, fever, or pain can also signal anaphylaxis, thrombosis, hemolysis, pulmonary injury, infection, or another emergency.
- Baseline assessment
- Rate-related reaction
- Premedication
- Anaphylaxis
- Emergency stop rules
- Rechallenge
Slow or stop immediately while airway, breathing, and circulation are assessed
Separate rate symptoms from anaphylaxis, vascular, pulmonary, and hemolytic events
Use epinephrine promptly for anaphylaxis and escalate emergencies
Document phenotype, product, rate, intervention, outcome, and rechallenge decision
Reassess before every infusion
Review prior product and reaction, current illness, hydration, renal and cardiovascular status, thrombosis risk, weight, dose, new medicines, and whether the planned site or line remains appropriate.
Use rate modification deliberately
For a mild probable rate-related reaction, pause or slow according to protocol, assess vital signs and symptoms, treat when needed, and resume only after improvement at a safer rate.
Do not let premedication replace diagnosis
Acetaminophen, antihistamine, corticosteroid, hydration, or split dosing may help selected recurrent reactions. Routine stacking can add adverse effects and may obscure an evolving serious event.
Treat anaphylaxis as an emergency
Stop the product, support airway and circulation, give intramuscular epinephrine promptly when anaphylaxis is present, activate emergency care, and do not restart the same infusion casually.
Investigate delayed symptoms
Severe headache with neck stiffness, dark urine, jaundice, reduced urine, chest pain, focal neurologic symptoms, hypoxemia, or progressive dyspnea after treatment requires urgent syndrome-specific evaluation.
Quick check
Lesson
Recognize the High-Consequence Syndromes
Immune globulin can cause thrombosis, kidney injury, hemolysis, aseptic meningitis, anaphylaxis, hyperviscosity complications, volume stress, and transfusion-related acute lung injury. Risk reduction starts before exposure and continues after discharge.
- Thrombosis
- Kidney injury
- Hemolysis
- Aseptic meningitis
- TRALI
- Hyperviscosity
Use hydration, minimum practical rate, mobility, and symptom surveillance
Match product and rate to renal function, volume, and nephrotoxins
Recognize delayed laboratory and neurologic syndromes
Stop treatment and distinguish noncardiogenic injury from volume stress
Prevent thrombosis without false reassurance
Events can occur without known risk factors. Use the minimum dose and rate practicable for at-risk patients, ensure appropriate hydration, avoid unnecessary immobility, recognize estrogen, vascular catheter, hypercoagulability, hyperviscosity, age, and cardiovascular risks, and act on symptoms.
Protect kidney function
Assess creatinine, urine output, volume, diabetes, sepsis, paraproteinemia, age, nephrotoxins, and product formulation. Use a safer product and slower rate when indicated. Do not assume every current product contains sucrose.
Detect hemolysis
High cumulative dose, inflammation, and non-O blood group can increase risk. Evaluate falling hemoglobin, jaundice, dark urine, elevated bilirubin or LDH, low haptoglobin, reticulocytosis, and direct antiglobulin findings in context.
Recognize aseptic meningitis
Severe headache, photophobia, neck stiffness, nausea, fever, and cerebrospinal fluid pleocytosis can occur after immune globulin. Exclude infection, hemorrhage, thrombosis, and other urgent causes.
Evaluate respiratory injury
New hypoxemia and noncardiogenic pulmonary edema within hours can indicate TRALI, while heart failure or volume overload produces a different mechanism. Stop therapy and provide urgent respiratory evaluation.
Quick check
Lesson
Monitor the Patient, Not a Universal Trough
Monitoring depends on indication, route, product, organ risk, and treatment phase. Passive antibodies can also distort serologic tests and blunt selected live vaccine responses long after an infusion.
- Clinical endpoint
- IgG exposure
- Laboratory interference
- Vaccine timing
- Viscosity
- Adverse-event surveillance
Track infections or disease-specific function before chasing a number
Interpret route, dose, interval, collection time, and protein loss
Identify passively transferred antibodies before diagnosing disease
Use CDC product- and dose-specific intervals for MMR and varicella
Lead with the disease endpoint
For replacement, track infections, antimicrobial use, hospitalization, lung status, function, adherence, and IgG exposure. For immunomodulation, use the disease-specific response and toxicity endpoint.
Interpret IgG by route and time
A concentration has meaning only with product, route, dose, interval, collection time, protein loss, infection status, and clinical course. Do not chase one population target without context.
Expect passive serology
Transferred antibodies can create positive infectious, autoimmune, blood group, or other serologic results that do not represent the recipient's own antibody production. Record treatment date and consult the laboratory.
Use CDC vaccine intervals
Non-live vaccines generally do not require separation. MMR and varicella timing after antibody-containing products is dose and indication dependent, with CDC intervals that can extend from months to nearly a year after high-dose therapy.
Target viscosity assessment
Measure or assess viscosity when hyperviscosity risk is clinically meaningful, such as selected paraproteinemias, cryoglobulinemia, very high triglycerides, or prior hyperviscosity, rather than ordering it for everyone.
Quick check
Lesson
Adapt the System for Patient-Specific Risk
Age, pregnancy, obesity, kidney and cardiac disease, diabetes, thrombosis risk, protein loss, pediatric needs, and home support can change product, route, rate, dose calculation, monitoring, and site of care.
- Pediatrics
- Older adults
- Pregnancy and lactation
- Obesity
- Renal disease
- Cardiovascular disease
Respect product age limits, growth, frailty, organ function, and support
State the dosing weight and balance hydration with cardiac tolerance
Select concentration, rate, dose division, setting, and monitoring together
Use current narrative evidence and disease guidance, never legacy letters
Use pediatric product boundaries
Verify the product's approved age, indication, dose, maximum rate, volume, site limits, and caregiver training. Weight change and developmental ability can alter both prescription and home technique.
Protect older adults
Advanced age often clusters renal, vascular, cardiac, mobility, and polypharmacy risks. Use the minimum dose and rate practicable when indicated, hydrate thoughtfully, and monitor closely without causing volume overload.
Use pregnancy and lactation evidence carefully
Immune globulin is used during pregnancy for selected maternal and fetal indications, but product labels and disease guidance should direct therapy. Avoid obsolete pregnancy letters and coordinate maternal, fetal, thrombotic, renal, and vaccine considerations.
Make obesity dosing transparent
Dose-weight strategies are debated and indication dependent. State the weight method, calculate the exact grams, assess response and toxicity, and avoid both automatic dose capping and unexamined actual-weight escalation.
Balance hydration with organ function
Adequate hydration can reduce renal and thrombotic risk, but aggressive fluid can worsen heart failure. Choose product concentration, route, rate, divided dosing, and monitoring as one integrated plan.
Quick check
Lesson
Make Every Transition Clinically Visible
A different brand, route, concentration, setting, payer, supply source, or schedule is a treatment transition. Continuity requires reconciliation, conversion, training, traceability, and a shared plan for response and toxicity.
- Product reconciliation
- Home transition
- Supply changes
- Stewardship
- Handoff
- Emergency plan
Capture product, route, grams, rate, sites, lot, reactions, and response
Recheck conversion, label, risk, equipment, training, and observation
Prevent duplication, optimize interval, reduce waste, and define renewal
Name responsibility for supply, labs, vaccines, adverse events, and follow-up
Reconcile the full exposure
Record indication, exact brand, route, concentration, grams, weight basis, interval, last dose, rates, sites, lots, premedication, reactions, clinical response, laboratory timing, and next dose.
Treat substitution as a new start
When product or route changes, verify the label, conversion, infusion instructions, risk factors, supply, equipment, training, and observation plan. Familiarity with the class does not prove tolerance of the new system.
Use scarce biologic therapy responsibly
Confirm ongoing indication, optimize dose and interval to clinical response, avoid duplicate inpatient and outpatient doses, reduce waste through vial planning, and document renewal criteria.
Build the home safety net
Provide contact pathways for routine questions, failed access, missed or partial dose, pump problems, local reaction, systemic reaction, delayed serious symptoms, travel, storage excursion, and emergency care.
Close the handoff
Name the clinician and pharmacy responsible for orders, authorization, supply, laboratory review, infusion records, adverse events, vaccines, and reassessment. A list of doses without ownership is not continuity.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 160 question bank.
Each attempt draws a fresh set and rearranges the answer choices.